– CANADA, Calgary – Zylorion Health Inc., a precision mental health care and psychedelic therapy-focused innovator, today announced the addition of Jeroen Tas to its Board of Directors.
About Jeroen Tas
Mr. Tas previously served as Chief Innovation and Strategy Officer with Koninklijke Philips N.V. (NYSE: PHG) (AMS: PHIA), a leading global health technology company. Before joining Philips, Mr. Tas co-founded and served as President, COO, and Vice-Chairman of Mphasis Ltd., a global technology solutions company. Mr. Tas also led Transaction Technology Inc., Citi’s tech lab, where he oversaw the first launch of internet banking, new payment networks, and internet-based self-service devices.
Mr. Tas previously served as an observer to Zylorion’s Board of Directors and as a Digital Health Advisory Committee member.
About Zylorion
Zylorion is a biotech company engaged in developing and delivering integrated precision mental health therapies to address psychological and neurological mental health conditions. developing and delivering Zylorion is focused on the research, development, and commercialization of psychedelic-based compounds coupled with novel therapeutic treatment programs targeting a continuum of mental health conditions, such as MDD (major depressive disorder), TRD (treatment-resistant depression), PTSD (post-traumatic stress disorder), general depression, anxiety disorders, and a number of addictive tendencies. Zylorion aims to leverage leading technologies to support the scalability and accessibility of its integrated therapy programs in its mission to enable those experiencing mental health challenges to thrive.
For more information : https://www.zylorion.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
